When the Oxford-AstraZeneca vaccine released its initial clinical results, it was hailed as a necessary and game-changing candidate. Compared to the vaccine race’s other “winners”, Pfizer and Moderna, AstraZeneca was widely viewed as an accessible, affordable alternative that required less stringent storage conditions.  Like other leading vaccines, the AstraZeneca shot can drastically reduce severe or fatal cases of Covid-19. 
Today, the global vaccine rollout is well underway. It is also wildly unequal. While the United States and 42 other mostly high-income countries are on track to vaccinate their entire populations within the year, 67 low-income countries have not vaccinated anyone at all.